Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Wave Life Sciences Ltd’s stock clocked out at $7.03, up 2.63% from its previous closing price of $6.85. In other words, the price has increased by $2.63 from its previous closing price. On the day, 0.77 million shares were traded. WVE stock price reached its highest trading level at $7.0999 during the session, while it also had its lowest trading level at $6.8.
Ratios:
To gain a deeper understanding of WVE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.95 and its Current Ratio is at 2.95. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.09.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $10.
On April 08, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $18.Wedbush initiated its Outperform rating on April 08, 2025, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when Verdine Gregory L. sold 30,000 shares for $6.95 per share. The transaction valued at 208,500 led to the insider holds 282,517 shares of the business.
GREGORY VERDINE bought 30,000 shares of WVE for $216,000 on Jun 13 ’25. On Mar 20 ’25, another insider, HENRY CHRISTIAN O, who serves as the Director of the company, sold 10,500 shares for $9.77 each. As a result, the insider received 102,574 and left with 16,115 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WVE now has a Market Capitalization of 1093607936 and an Enterprise Value of 871961024. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.42 while its Price-to-Book (P/B) ratio in mrq is 6.31. Its current Enterprise Value per Revenue stands at 8.309 whereas that against EBITDA is -7.146.
Stock Price History:
The Beta on a monthly basis for WVE is -1.03, which has changed by 0.40881765 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, WVE has reached a high of $16.74, while it has fallen to a 52-week low of $4.25. The 50-Day Moving Average of the stock is 5.36%, while the 200-Day Moving Average is calculated to be -30.12%.
Shares Statistics:
It appears that WVE traded 1.46M shares on average per day over the past three months and 899300 shares per day over the past ten days. A total of 154.09M shares are outstanding, with a floating share count of 124.26M. Insiders hold about 20.12% of the company’s shares, while institutions hold 80.71% stake in the company. Shares short for WVE as of 1749772800 were 14881762 with a Short Ratio of 10.16, compared to 1747267200 on 15449847. Therefore, it implies a Short% of Shares Outstanding of 14881762 and a Short% of Float of 13.05.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Wave Life Sciences Ltd (WVE) is a result of the insights provided by 9.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.23 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.86 and -$1.15 for the fiscal current year, implying an average EPS of -$1.04. EPS for the following year is -$1.08, with 9.0 analysts recommending between -$0.86 and -$1.26.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $11.52M. It ranges from a high estimate of $18M to a low estimate of $5M. As of the current estimate, Wave Life Sciences Ltd’s year-ago sales were $19.69MFor the next quarter, 9 analysts are estimating revenue of $12.99M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $5M.
A total of 10 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $94.2M, while the lowest revenue estimate was $38.17M, resulting in an average revenue estimate of $58.7M. In the same quarter a year ago, actual revenue was $108.3M
